Skip Navigation LinksHome > March 2001 - Volume 21 - Issue 1 > Increased Endothelin-1 Plasma Levels in Patients With Multip...
Journal of Neuro-Ophthalmology:
Article

Increased Endothelin-1 Plasma Levels in Patients With Multiple Sclerosis

Haufschild, Timo MD; Shaw, Sidney G. PhD; Kesselring, Jürg MD; Flammer, Josef MD

Free Access
Article Outline
Collapse Box

Author Information

From the University Eye Clinic (TH, JF), Basel, Switzerland; Department of Clinical Research (SGS), University of Berne, Berne, Switzerland; and Department of Neurorehabilitation (JK), Rehabilitation Centre, Valens, Switzerland.

Manuscript received September 23, 1999; accepted January 9, 2001.

Address correspondence and reprint requests to Prof. J. Flammer, University Eye Clinic, Mittlere Str. 91, PO Box, CH-4012 Basel, Switzerland; e-mail: Josef.Flammer@ubaclu.unibas.ch.

Collapse Box

Abstract

Objective: We tested the hypothesis that the plasma level of endothelin-1 (ET-1) is increased in patients with multiple sclerosis (MS). The peptide ET-1 is one of the most potent known vasoconstrictors. An increased level of endothelin could explain some of the vascular symptoms of these patients.

Materials and Methods: A specific radioimmunoassay was used to determine ET-1 plasma levels. Twenty patients with MS were compared to 20 age-and sex-pair-matched healthy subjects.

Results: The plasma ET-1 levels were, on average, 224% higher in the patients with MS than in the controls (p < 0.005). The mean ET-1 levels (mean ± standard deviation [SD]) were 3.5 ± 0.83 pg/mL (min 2.13, max 5.37 pg/mL) in patients with MS and 1.56 ± 0.3 pg/mL (min 0.9, max 2.13 pg/mL) in healthy volunteers. Neither the different forms nor stages of MS had an influence on the results. The ET-1 level was also not correlated with the duration of the disease.

Conclusions: The plasma ET-1 level is markedly and significantly increased in patients with MS. Neither the cause of such an increase nor the pathogenetic role is known.

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system in which autoimmune mechanisms are relevant. In some patients with MS, signs of a vascular dysregulation can be observed (e.g., patients with MS show symptoms such as a tendency to cold extremities and migraine more often than healthy people) (1,2). This observation would be compatible with an increase of plasma ET-1. Furthermore, the possible involvement of vascular factors in the pathogenesis of the brain lesions or the symptoms has been discussed with controversy for decades (3,4).

The peptide endothelin-1 (ET-1), produced and released mostly but not exclusively by endothelial cells, is one of the most potent known physiologic vasoconstrictors. Because an increased plasma level of ET-1 could explain some of the vascular symptoms of patients with MS and because increased levels of endothelin were described in the cerebrospinal fluid of patients with MS (5), we tested the hypothesis that patients with MS have increased ET-1 plasma levels.

Back to Top | Article Outline

METHODS

The ET-1 plasma levels of patients with clinically defined MS (6)(10 males, mean age 43.8 ± 14.7 years, range 21–68 years and 10 females, mean age 41.6 ± 11.5 years, range 23–56 years) have been compared with the levels of healthy volunteers (10 males, mean age 45 ± 14.1 years, range 27–69 years and 10 females, mean age 41.7 ± 11.1 years, range 23–55 years). All patients with systemic conditions known to be associated with increased ET-1 levels were excluded from the study (7). At the moment blood was taken, all patients were mobile and in a stable phase of their disease. None had experienced a clinical relapse for at least 3 months. No patient was on any systematic medication. Written informed consent was obtained from all patients. Blood samples were taken after 30 minutes of rest in a supine position at room temperature. ET-1 plasma levels were determined by specific radioimmunoassay, as previously described (8). All values are expressed as mean ± standard deviation (SD). The ET-1 level of patients with MS was compared to age-and sex-pair-matched healthy subjects with the help of a dependent t-test. The influence of stages and types of MS were tested with an analysis of variance. The correlation with age and duration of MS was done with a Pearson correlation. A p value less than 0.05 was considered to be significant.

Back to Top | Article Outline

RESULTS

Plasma ET-1 levels were markedly and significantly elevated, by 224%, in patients with MS (p < 0.005) and averaged 3.5 ± 0.83 pg/mL (min 2.13, max 5.37 pg/mL) compared to 1.56 ± 0.3 pg/mL (min 0.9, max 2.13 pg/mL) in age-and sex-matched healthy volunteers (Fig. 1).

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline

DISCUSSION

Our study shows that patients with MS have markedly increased ET-1 plasma levels. No correlation to age could be found in healthy subjects or patients with MS. The different forms of MS and the different stages had no significant influence on the results. No correlation to the duration of the disease or to the mean Kurtzke Expanded Disability Status Scale (EDSS) could be found. An increased ET-1 plasma level in patients with MS goes with the finding of increased endothelin levels in the cerebrospinal fluid of patients with MS (5). Whether the increased ET-1 levels in patients with MS reflect an increased ET-1 production, a decreased metabolism, or a decreased excretion is not yet clear. An increase in ET-1 plasma level is not specific for MS. Similar plasma levels have been reported in patients with other autoimmune diseases, such as antiphospholipid syndrome, rheumatoid arthritis, and lupus erythematosus, and also in some infectious diseases, such as AIDS (7). Although increased endothelin levels were also found in the cerebrospinal fluid of patients with MS, the possible role of endothelin for neural transmission and regulation is not known and needs to be further investigated. In diabetic neuropathy, increased ET-1 activity exacerbates neural degeneration (reduction of nerve conduction velocity and endoneural blood flow) (9). In the case that ET-1 plays a role in the pathogenesis of MS, endothelin receptor blockers may offer some additional options.

Back to Top | Article Outline

Acknowledgments:

The authors thank J. Boden, M. Joos, S. Lengen, and A. Zosso for expert technical assistance. This work was supported by the Swiss National Science Foundation (grant 32-49648.96).

Back to Top | Article Outline

REFERENCES

1. Watkins S, Espir M. Migraine and multiple sclerosis. J Neurol Neurosurg Psych 1969; 32:35–7.

2. Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. Can J Neurol Sci 1989; 16:63–6.

3. Putnam TJ. The pathogenesis of multiple sclerosis: a possible vascular factor. N Engl J Med 1933; 209:786–90.

4. James PB. Multiple sclerosis or blood-brain barrier disease. Lancet 1989; 1:46.

5. Speciale L, Sarasella M, Ruzzante S, et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 2000; 6(suppl 2):S62–6.

6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227–31.

7. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Ret Eye Res, in press.

8. Barton M, Shaw SG, d'Uscio L, et al. Angiotensin increases vascular and retinal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Comm 1997; 238:861–5.

9. Cameron NE, Dines KC, Cotter MA. The potential contribution of endothelin-1 to neurovascular abnormalities in streptozoticin-diabetic rats. Diabetologia 1994; 37:1209–15.

Cited By:

This article has been cited 24 time(s).

Current Opinion in Pharmacology
New insights in the pathogenesis and treatment of normal tension glaucoma
Mozaffarieh, M; Flammer, J
Current Opinion in Pharmacology, 13(1): 43-49.
10.1016/j.coph.2012.10.001
CrossRef
Journal of Pharmacology and Experimental Therapeutics
Endothelin-1-Induced Endoplasmic Reticulum Stress in Disease
Jain, A
Journal of Pharmacology and Experimental Therapeutics, 346(2): 163-172.
10.1124/jpet.113.205567
CrossRef
Multiple Sclerosis Journal
MS risk genes are transcriptionally regulated in CSF leukocytes at relapse
Jernas, M; Malmestrom, C; Axelsson, M; Olsson, C; Nookaew, I; Wadenvik, H; Zetterberg, H; Blennow, K; Lycke, J; Rudemo, M; Olsson, B
Multiple Sclerosis Journal, 19(4): 403-410.
10.1177/1352458512455466
CrossRef
Ophthalmologica
Transient raise of endothelin-1 plasma level and reduction of ocular blood flow in a patient with optic neuritis
Haufschild, T; Shaw, SG; Kaiser, HJ; Flammer, J
Ophthalmologica, 217(6): 451-453.
10.1159/000073079
CrossRef
Archives of Ophthalmology
Peripheral Artery Disease and Glaucoma The Singapore Malay Eye Study
Jeganathan, VSE; Wong, TY; Foster, PJ; Crowston, JG; Tay, WT; Lim, SC; Saw, SM; Tai, ES; Aung, T
Archives of Ophthalmology, 127(7): 888-893.

Annals of Neurology
Influence of red wine on visual function and endothelin-1 plasma level in a patient with optic neuritis
Haufschild, T; Kaiser, HJ; Preisig, T; Pruente, C; Flammer, J
Annals of Neurology, 53(6): 825-826.
10.1002/ana.10602
CrossRef
Journal of Neuroscience Research
Transient 5-(4-phenylbutoxy)psoralen (PAP-1) treatment dissociates developing pathologies in autoimmune optic neuritis into two distinct pathology profiles
Stokely, ME; Garg, P; Bhat, MA; Koulen, P
Journal of Neuroscience Research, 86(9): 2111-2124.
10.1002/jnr.21645
CrossRef
European Neurology
Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis
Pache, M; Kaiser, HJ; Akhalbedashvili, N; Lienert, C; Dubler, B; Kappos, L; Flammer, J
European Neurology, 49(3): 164-168.
10.1159/000069085
CrossRef
Klinische Monatsblatter Fur Augenheilkunde
Retinal Vessels in Patients with Multiple Sclerosis: Baseline Diameter and Response to Flicker Light Stimulation
Gugleta, K; Kochkorov, A; Kavroulaki, D; Katamay, R; Weier, K; Mehling, M; Kappos, L; Flammer, J; Orgul, S
Klinische Monatsblatter Fur Augenheilkunde, 226(4): 272-275.
10.1055/s-0028-1109289
CrossRef
Klinische Monatsblatter Fur Augenheilkunde
Rigidity of Retinal Vessels in Patients with Multiple Sclerosis
Kochkorov, A; Gugleta, K; Kavroulaki, D; Katamay, R; Weier, K; Mehling, M; Kappos, L; Flammer, J; Orgul, S
Klinische Monatsblatter Fur Augenheilkunde, 226(4): 276-279.
10.1055/s-0028-1109291
CrossRef
Magnesium Research
Importance of magnesium depletion with hypofunction of the biological clock in the pathophysiology of headhaches with photophobia, sudden infant death and some clinical forms of multiple sclerosis
Durlach, J; Pages, N; Bac, P; Bara, M; Guiet-Bara, A
Magnesium Research, 17(4): 314-326.

Acta Ophthalmologica Scandinavica
Reduced thirst in patients with a vasospastic syndrome
Teuchner, B; Orgul, S; Ulmer, H; Haufschild, T; Flammer, J
Acta Ophthalmologica Scandinavica, 82(6): 738-740.

Lancet Neurology
Symptomatic therapy and neurorehabilitation in multiple sclerosis
Kesselring, J; Beer, S
Lancet Neurology, 4(): 643-652.

Survey of Ophthalmology
What is the link between vascular dysregulation and glaucoma?
Grieshaber, MC; Mozaffarieh, M; Flammer, J
Survey of Ophthalmology, 52(): S144-S154.
10.1016/j.survophthal.2007.08.010
CrossRef
Survey of Ophthalmology
The Potential Value of Natural Antioxidative Treatment in Glaucoma
Mozaffarieh, M; Grieshaber, MC; Orgul, S; Flammer, J
Survey of Ophthalmology, 53(5): 479-505.
10.1016/j.survophthal.2008.06.006
CrossRef
Journal of the Neurological Sciences
Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?
Kirk, S; Frank, JA; Karlik, S
Journal of the Neurological Sciences, 217(2): 125-130.
10.1016/j.jns.2003.10.016
CrossRef
Molecular Vision
Oxygen and blood flow: players in the pathogenesis of glaucoma
Mozaffarieh, M; Grieshaber, MC; Flammer, J
Molecular Vision, 14(): 224-233.

American Journal of Hypertension
Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects
Abdel-Sayed, S; Nussberger, L; Aubert, JF; Gohlke, P; Brunner, HR; Brakch, N
American Journal of Hypertension, 16(7): 515-521.
10.1016/S0895-7061(03)00903-8
CrossRef
Journal of Neurology
Neurorehabilitation in multiple sclerosis what is the evidence-base?
Kesselring, J
Journal of Neurology, 251(): 25-29.
10.1007/s00415-004-1405-0
CrossRef
Survey of Ophthalmology
What is the present pathogenetic concept of glaucomatous optic neuropathy?
Flammer, J; Mozaffarieh, M
Survey of Ophthalmology, 52(): S162-S173.
10.1016/j.survophthat.2007.08.012
CrossRef
Journal of Autoimmunity
VEGF and vascular changes in chronic neuroinflammation
Kirk, SL; Karlik, SJ
Journal of Autoimmunity, 21(4): 353-363.
10.1016/S0896-8411(03)00139-2
CrossRef
Journal of Neuroscience Methods
Microfluorimetry defines early axonal damage in a rat model of optic neuritis: A novel method targeting early CNS autoimmunity
Stokely, ME; Bhat, MA; Koulen, P
Journal of Neuroscience Methods, 166(2): 217-228.
10.1016/j.jneumeth.2007.07.010
CrossRef
Progress in Retinal and Eye Research
The impact of ocular blood flow in glaucoma
Flammer, J; Orgul, S; Costa, VP; Orzalesi, N; Krieglstein, GK; Serra, LM; Renard, JP; Stefansson, E
Progress in Retinal and Eye Research, 21(4): 359-393.
PII S1350-9462(02)00008-3
CrossRef
Proceedings of the National Academy of Sciences of the United States of America
Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1
D'haeseleer, M; Beelen, R; Fierens, Y; Cambron, M; Vanbinst, AM; Verborgh, C; Demey, J; De Keyser, J
Proceedings of the National Academy of Sciences of the United States of America, 110(): 5654-5658.
10.1073/pnas.1222560110
CrossRef
Back to Top | Article Outline
Keywords:

Multiple sclerosis; Endothelin-1; Vascular dysregulation

© 2001 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.